You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNilotinib
Accession NumberDB04868
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment. [Wikipedia]
Structure
Thumb
Synonyms
Nilotinibum
External Identifiers
  • AMN 107
  • AMN-107
  • AMN107
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TasignaCapsule150 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Pharmaceuticals Canada Inc2008-09-30Not applicableCanada
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule150 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule150 mgOralNovartis Pharmaceuticals Canada Inc2011-07-15Not applicableCanada
TasignaCapsule200 mg/1OralNovartis Pharmaceuticals Corporation2007-10-29Not applicableUs
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule150 mg/1OralNovartis Pharmaceuticals Corporation2007-10-29Not applicableUs
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule150 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule150 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule150 mgOralNovartis Europharm Ltd2007-11-19Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nilotinib hydrochloride monohydrate
923288-90-8
Thumb
  • InChI Key: YCBPQSYLYYBPDW-UHFFFAOYSA-N
  • Monoisotopic Mass: 583.1710353
  • Average Mass: 584.0
DBSALT001325
Categories
UNIIF41401512X
CAS number641571-10-0
WeightAverage: 529.5158
Monoisotopic: 529.183792976
Chemical FormulaC28H22F3N7O
InChI KeyHHZIURLSWUIHRB-UHFFFAOYSA-N
InChI
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
IUPAC Name
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide
SMILES
CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
Pharmacology
IndicationFor the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
Structured Indications Not Available
PharmacodynamicsNilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
Mechanism of actionChronic myelogenous leukaemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein. Nilotinib fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib, over-riding resistance caused by mutations. The ability of AMN107 to inhibit TEL-platelet-derived growth factor receptor-beta (TEL-PDGFRbeta), which causes chronic myelomonocytic leukaemia, and FIP1-like-1-PDGFRalpha, which causes hypereosinophilic syndrome, suggests potential use of AMN107 for myeloproliferative diseases characterised by these kinase fusions (Stover et al, 2005; Weisberg et al, 2005). AMN107 also inhibits the c-Kit receptor kinase, including the D816V-mutated variant of KIT, at pharmacologically achievable concentrations, supporting potential utility in the treatment of mastocytosis, and gastrointestinal stromal tumours (Weisberg et al, 2005; von Bubnoff et al, 2005; Gleixner et al, 2006).
TargetKindPharmacological actionActionsOrganismUniProt ID
Tyrosine-protein kinase ABL1Proteinyes
inhibitor
HumanP00519 details
Mast/stem cell growth factor receptor KitProteinunknown
antagonist
HumanP10721 details
Related Articles
AbsorptionOrally available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life15 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nilotinib.Experimental, Illicit
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Nilotinib.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Nilotinib.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Nilotinib.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nilotinib.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Nilotinib.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nilotinib.Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Nilotinib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Nilotinib.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nilotinib.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Nilotinib.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nilotinib.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Nilotinib.Experimental
AjmalineThe metabolism of Ajmaline can be decreased when combined with Nilotinib.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Nilotinib.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Nilotinib.Approved
AldosteroneThe serum concentration of Nilotinib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Nilotinib can be increased when it is combined with Alectinib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Nilotinib.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Nilotinib.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nilotinib.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Nilotinib.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nilotinib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Nilotinib.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Nilotinib.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Nilotinib.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Nilotinib.Approved, Withdrawn
ALT-110The risk or severity of adverse effects can be increased when Nilotinib is combined with ALT-110.Investigational
Aluminum hydroxideThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum phosphate.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Nilotinib.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Nilotinib.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Nilotinib.Approved
Aminohippuric acidThe serum concentration of Nilotinib can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nilotinib.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Nilotinib.Approved
AmiodaroneThe serum concentration of Nilotinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Nilotinib.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Nilotinib.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nilotinib.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Nilotinib.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Nilotinib.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Nilotinib.Approved
AmsacrineThe serum concentration of Nilotinib can be increased when it is combined with Amsacrine.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Nilotinib.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nilotinib.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Nilotinib.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nilotinib.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Nilotinib.Approved, Investigational
AprepitantThe serum concentration of Nilotinib can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Nilotinib.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Nilotinib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nilotinib.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
ArtemetherNilotinib may increase the QTc-prolonging activities of Artemether.Approved
AsenapineThe serum concentration of Nilotinib can be decreased when it is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Nilotinib.Approved, Withdrawn
AtazanavirThe serum concentration of Nilotinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Nilotinib can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Nilotinib.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Nilotinib.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Nilotinib.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Nilotinib.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Nilotinib.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Nilotinib.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Nilotinib.Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Nilotinib.Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Nilotinib.Investigational
BedaquilineBedaquiline may increase the QTc-prolonging activities of Nilotinib.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Nilotinib.Approved
BenzocaineThe serum concentration of Nilotinib can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Nilotinib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Nilotinib.Approved
BepridilThe serum concentration of Nilotinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Nilotinib.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nilotinib.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Nilotinib.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Nilotinib.Approved, Investigational
BexaroteneThe serum concentration of Nilotinib can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Nilotinib.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Nilotinib.Approved
BiperidenThe serum concentration of Nilotinib can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe serum concentration of Nilotinib can be decreased when it is combined with Bismuth Subcitrate.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Nilotinib.Approved
BoceprevirThe serum concentration of Nilotinib can be increased when it is combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Nilotinib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nilotinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nilotinib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Nilotinib.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Nilotinib.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Nilotinib.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Nilotinib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Nilotinib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Nilotinib.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Nilotinib.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Nilotinib.Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Nilotinib.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Nilotinib.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Nilotinib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Nilotinib.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Nilotinib.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Nilotinib.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Nilotinib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nilotinib.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Nilotinib.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Nilotinib.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Nilotinib.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Nilotinib.Approved, Nutraceutical
Calcium carbonateThe serum concentration of Nilotinib can be decreased when it is combined with Calcium carbonate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nilotinib.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Nilotinib.Approved
CandesartanThe serum concentration of Nilotinib can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Nilotinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Nilotinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Nilotinib.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nilotinib.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Nilotinib.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Nilotinib.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Nilotinib.Approved, Investigational
CaspofunginThe serum concentration of Nilotinib can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Nilotinib.Experimental
CDX-110The risk or severity of adverse effects can be increased when Nilotinib is combined with CDX-110.Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Nilotinib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Nilotinib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Nilotinib.Approved, Vet Approved
CeritinibThe serum concentration of Nilotinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Nilotinib.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Nilotinib.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Nilotinib.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Nilotinib.Approved, Illicit
ChloroquineChloroquine may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Nilotinib.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
ChlorpropamideThe serum concentration of Nilotinib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Nilotinib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Nilotinib.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Nilotinib.Approved, Nutraceutical
CholesterolThe serum concentration of Nilotinib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Nilotinib can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Nilotinib.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Nilotinib.Experimental
CilazaprilThe serum concentration of Nilotinib can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nilotinib.Approved
CimetidineThe serum concentration of Nilotinib can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Nilotinib.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Nilotinib.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nilotinib.Approved
CitalopramCitalopram may increase the QTc-prolonging activities of Nilotinib.Approved
ClarithromycinThe serum concentration of Nilotinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Nilotinib can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Nilotinib.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Nilotinib.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Nilotinib.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Nilotinib.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Nilotinib.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Nilotinib.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nilotinib.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Nilotinib.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Nilotinib.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Nilotinib.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Nilotinib.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Nilotinib.Approved, Illicit
ClotrimazoleThe metabolism of Nilotinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Nilotinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nilotinib.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Nilotinib.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Nilotinib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nilotinib.Approved
ColforsinThe serum concentration of Nilotinib can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Nilotinib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Nilotinib.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Nilotinib.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Nilotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Nilotinib.Approved, Investigational
CyclosporineThe metabolism of Nilotinib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Nilotinib.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nilotinib.Approved
DabrafenibThe serum concentration of Nilotinib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Nilotinib.Approved
DactinomycinThe serum concentration of Nilotinib can be increased when it is combined with Dactinomycin.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Nilotinib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Nilotinib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Nilotinib.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Nilotinib.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Nilotinib.Approved, Investigational
DarunavirThe serum concentration of Nilotinib can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nilotinib.Approved
DasatinibThe serum concentration of Nilotinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Nilotinib.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Nilotinib.Approved
DeferasiroxThe serum concentration of Nilotinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Nilotinib.Approved
DelavirdineThe metabolism of Nilotinib can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Nilotinib.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Nilotinib.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Nilotinib.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Nilotinib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Nilotinib.Approved
DesloratadineThe serum concentration of Nilotinib can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Nilotinib.Approved
DexamethasoneThe serum concentration of Nilotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Nilotinib.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Nilotinib.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Nilotinib.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Nilotinib.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Nilotinib.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Nilotinib.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Nilotinib.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nilotinib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Nilotinib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Nilotinib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Nilotinib.Approved, Illicit
DihydroergotamineThe metabolism of Nilotinib can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nilotinib.Illicit
DiltiazemThe metabolism of Nilotinib can be decreased when combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Nilotinib.Approved
DipyridamoleThe serum concentration of Nilotinib can be increased when it is combined with Dipyridamole.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Nilotinib.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Nilotinib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilotinib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Nilotinib.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Nilotinib.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nilotinib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Nilotinib.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Nilotinib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Nilotinib.Approved
DoxazosinThe serum concentration of Nilotinib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Nilotinib can be decreased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nilotinib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Nilotinib.Approved, Investigational
DoxycyclineThe metabolism of Nilotinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nilotinib.Approved, Illicit
DronedaroneDronedarone may increase the QTc-prolonging activities of Nilotinib.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nilotinib.Approved
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Nilotinib.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Nilotinib.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nilotinib.Approved
EfavirenzThe serum concentration of Nilotinib can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Nilotinib can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nilotinib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Nilotinib.Approved
EltrombopagThe serum concentration of Nilotinib can be increased when it is combined with Eltrombopag.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Nilotinib.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Nilotinib.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Nilotinib.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Nilotinib.Investigational
EnzalutamideThe serum concentration of Nilotinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Nilotinib can be decreased when it is combined with Epinastine.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Nilotinib.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Nilotinib.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Nilotinib.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Nilotinib.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Nilotinib.Approved
EribulinEribulin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Nilotinib.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Nilotinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Nilotinib.Investigational
EsomeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Nilotinib.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Nilotinib.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Nilotinib.Approved
EstriolThe serum concentration of Nilotinib can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Nilotinib.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Nilotinib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Nilotinib.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Nilotinib.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Nilotinib.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Nilotinib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Nilotinib.Approved, Illicit
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Nilotinib.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Nilotinib.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nilotinib.Approved, Investigational
EtravirineThe serum concentration of Nilotinib can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nilotinib.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Nilotinib.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Nilotinib.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nilotinib.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Nilotinib.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Nilotinib.Approved
FamotidineThe serum concentration of Nilotinib can be decreased when it is combined with Famotidine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Nilotinib.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Nilotinib.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Nilotinib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Nilotinib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nilotinib.Approved
FexofenadineThe serum concentration of Nilotinib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nilotinib.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Nilotinib.Approved
FingolimodNilotinib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Nilotinib.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Nilotinib.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Nilotinib.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Nilotinib.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Nilotinib.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Nilotinib.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Nilotinib.Approved
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Nilotinib.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Nilotinib.Approved, Withdrawn
FluphenazineThe serum concentration of Nilotinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Nilotinib.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Nilotinib.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Nilotinib.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Nilotinib.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Nilotinib.Approved
FluvoxamineThe metabolism of Nilotinib can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
FosamprenavirThe metabolism of Nilotinib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nilotinib can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Nilotinib.Approved
FosphenytoinThe serum concentration of Nilotinib can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Nilotinib.Approved, Investigational
Fusidic AcidThe serum concentration of Nilotinib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Nilotinib is combined with G17DT.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Nilotinib.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Nilotinib.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Nilotinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nilotinib.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Nilotinib.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
GenisteinThe serum concentration of Nilotinib can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Nilotinib is combined with GI-5005.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Nilotinib.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Nilotinib.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Nilotinib.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Nilotinib.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Nilotinib.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Nilotinib.Approved
GlycerolThe serum concentration of Nilotinib can be increased when it is combined with Glycerol.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Nilotinib.Approved
Gramicidin DThe serum concentration of Nilotinib can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nilotinib.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Nilotinib.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Nilotinib.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Nilotinib.Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Nilotinib.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Nilotinib.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Nilotinib.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Nilotinib.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Nilotinib.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Nilotinib.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nilotinib.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Nilotinib.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Nilotinib.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Nilotinib.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Nilotinib.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nilotinib.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Nilotinib.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Nilotinib.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Nilotinib.Approved
IdelalisibThe serum concentration of Nilotinib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nilotinib resulting in a loss in efficacy.Approved
IloperidoneNilotinib may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nilotinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Nilotinib.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Nilotinib.Approved, Investigational
IndacaterolIndacaterol may increase the QTc-prolonging activities of Nilotinib.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Nilotinib.Approved
IndinavirThe serum concentration of Nilotinib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Nilotinib can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Nilotinib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Nilotinib is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nilotinib.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Nilotinib.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nilotinib.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Nilotinib.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nilotinib.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nilotinib.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Nilotinib.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Nilotinib.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Nilotinib.Approved, Investigational
IsavuconazoniumThe metabolism of Nilotinib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nilotinib.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nilotinib.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Nilotinib.Approved
ItraconazoleThe serum concentration of Nilotinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Nilotinib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Nilotinib.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Nilotinib.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Nilotinib.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Nilotinib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Nilotinib.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Nilotinib.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Nilotinib.Approved
KetoconazoleThe serum concentration of Nilotinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Nilotinib.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nilotinib.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nilotinib.Approved, Investigational
LansoprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Nilotinib.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nilotinib.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Nilotinib is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nilotinib.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Nilotinib.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Nilotinib.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Nilotinib.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nilotinib.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Nilotinib.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Nilotinib.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Nilotinib.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Nilotinib.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Nilotinib.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Nilotinib.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Nilotinib.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Nilotinib.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Nilotinib.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nilotinib.Approved
LiothyronineThe serum concentration of Nilotinib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Nilotinib can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Nilotinib.Approved
LisinoprilThe serum concentration of Nilotinib can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Nilotinib.Approved
LithiumLithium may increase the QTc-prolonging activities of Nilotinib.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Nilotinib.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Nilotinib.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Nilotinib.Approved
LopinavirThe serum concentration of Nilotinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Nilotinib.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Nilotinib.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Nilotinib.Approved
LovastatinThe metabolism of Nilotinib can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nilotinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nilotinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineNilotinib may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Nilotinib.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Nilotinib.Approved
MagaldrateThe serum concentration of Nilotinib can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium Trisilicate.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Nilotinib.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Nilotinib.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Nilotinib.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Nilotinib.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Nilotinib.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Nilotinib.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Nilotinib.Approved
Megestrol acetateThe serum concentration of Nilotinib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nilotinib.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Nilotinib.Investigational, Withdrawn
MeprobamateThe serum concentration of Nilotinib can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Nilotinib.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Nilotinib.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Nilotinib.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Nilotinib.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Nilotinib.Approved, Illicit
MethanthelineThe serum concentration of Nilotinib can be decreased when it is combined with Methantheline.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Nilotinib.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nilotinib.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Nilotinib.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Nilotinib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Nilotinib.Approved, Vet Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Nilotinib.Approved, Investigational
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Nilotinib.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Nilotinib.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Nilotinib.Approved, Illicit, Withdrawn
MetiamideThe serum concentration of Nilotinib can be decreased when it is combined with Metiamide.Experimental
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nilotinib.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Nilotinib.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Nilotinib.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Nilotinib.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Nilotinib.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Nilotinib.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Nilotinib.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Nilotinib.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Nilotinib.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Nilotinib.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Nilotinib.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Nilotinib.Approved, Investigational
MitomycinThe serum concentration of Nilotinib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Nilotinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Nilotinib can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Nilotinib.Approved
ModafinilThe serum concentration of Nilotinib can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Nilotinib.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Nilotinib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Nilotinib.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Nilotinib.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Nilotinib.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Nilotinib.Approved
NafcillinThe serum concentration of Nilotinib can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nilotinib.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Nilotinib.Approved, Vet Approved
NaltrexoneThe serum concentration of Nilotinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Nilotinib.Approved, Vet Approved
NaringeninThe serum concentration of Nilotinib can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Nilotinib.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Nilotinib.Approved, Investigational
NefazodoneThe serum concentration of Nilotinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nilotinib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Nilotinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Nilotinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nilotinib can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Nilotinib.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Nilotinib.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Nilotinib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Nilotinib.Approved
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Nilotinib.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Nilotinib.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nilotinib.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Nilotinib.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Nilotinib.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Nilotinib.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Nilotinib.Approved, Vet Approved
NizatidineThe serum concentration of Nilotinib can be decreased when it is combined with Nizatidine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Nilotinib.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Nilotinib.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Nilotinib.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Nilotinib.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Nilotinib.Approved
OlanzapineThe serum concentration of Nilotinib can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Nilotinib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Nilotinib.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Nilotinib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nilotinib.Approved
OmeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Nilotinib.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Nilotinib.Approved
OsimertinibThe serum concentration of Nilotinib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Nilotinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Nilotinib.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Nilotinib.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Nilotinib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Nilotinib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
P-NitrophenolThe serum concentration of Nilotinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nilotinib.Approved, Vet Approved
PalbociclibThe serum concentration of Nilotinib can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the QTc-prolonging activities of Nilotinib.Approved
Palmitic AcidThe serum concentration of Nilotinib can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Nilotinib.Approved, Investigational
PanobinostatPanobinostat may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
PantoprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nilotinib.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Nilotinib.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Nilotinib.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Nilotinib.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Nilotinib.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Nilotinib.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nilotinib.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Nilotinib.Approved
PentobarbitalThe serum concentration of Nilotinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Nilotinib.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Nilotinib.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Nilotinib.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Nilotinib.Approved
PerindoprilThe serum concentration of Nilotinib can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Nilotinib.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Nilotinib.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Nilotinib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nilotinib.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Nilotinib.Approved, Withdrawn
PhenobarbitalThe serum concentration of Nilotinib can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Nilotinib.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nilotinib.Approved
PhenytoinThe serum concentration of Nilotinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Nilotinib.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nilotinib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nilotinib.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Nilotinib.Withdrawn
PindololThe metabolism of Pindolol can be decreased when combined with Nilotinib.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Nilotinib.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Nilotinib.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Nilotinib.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Nilotinib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nilotinib.Approved
Platelet Activating FactorThe serum concentration of Nilotinib can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Nilotinib.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Nilotinib.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Nilotinib.Approved
PosaconazoleThe serum concentration of Nilotinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Nilotinib.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Nilotinib.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Nilotinib.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Nilotinib.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Nilotinib.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Nilotinib.Approved, Vet Approved
PrazosinThe serum concentration of Nilotinib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Nilotinib.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Nilotinib.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Nilotinib.Approved
PrimidoneThe serum concentration of Nilotinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Nilotinib can be increased when it is combined with Probenecid.Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Nilotinib.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Nilotinib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Nilotinib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Nilotinib.Approved
PromazinePromazine may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Nilotinib.Approved
PropafenoneThe serum concentration of Nilotinib can be increased when it is combined with Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Nilotinib.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Nilotinib.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nilotinib.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Nilotinib.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Nilotinib.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Nilotinib.Approved, Illicit
QuercetinThe serum concentration of Nilotinib can be increased when it is combined with Quercetin.Experimental
QuetiapineQuetiapine may increase the QTc-prolonging activities of Nilotinib.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Nilotinib.Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Nilotinib.Approved
QuinineQuinine may increase the QTc-prolonging activities of Nilotinib.Approved
RabeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Nilotinib.Approved
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Nilotinib.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Nilotinib.Approved, Investigational
RanitidineThe serum concentration of Nilotinib can be decreased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nilotinib.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Nilotinib.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Nilotinib.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Nilotinib.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Nilotinib.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Nilotinib.Investigational
ReserpineThe serum concentration of Nilotinib can be decreased when it is combined with Reserpine.Approved
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Nilotinib.Approved
RifabutinThe serum concentration of Nilotinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Nilotinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nilotinib can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nilotinib.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Nilotinib.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Nilotinib.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Nilotinib.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
RitonavirThe serum concentration of Nilotinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Nilotinib.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nilotinib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Nilotinib.Approved
RolapitantThe serum concentration of Nilotinib can be increased when it is combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Nilotinib.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Nilotinib.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Nilotinib.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Nilotinib.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Nilotinib.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Nilotinib.Approved
Roxatidine acetateThe serum concentration of Nilotinib can be decreased when it is combined with Roxatidine acetate.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Nilotinib.Approved, Withdrawn
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Nilotinib.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Nilotinib.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Nilotinib.Approved
SaquinavirThe serum concentration of Nilotinib can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Nilotinib.Approved
ScopolamineThe serum concentration of Nilotinib can be increased when it is combined with Scopolamine.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Nilotinib.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nilotinib.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Nilotinib.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Nilotinib.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Nilotinib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Nilotinib can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nilotinib.Approved
SiltuximabThe serum concentration of Nilotinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Nilotinib.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Nilotinib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nilotinib.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Nilotinib.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Nilotinib.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nilotinib.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Nilotinib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Nilotinib.Approved, Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Nilotinib.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nilotinib.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Nilotinib.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nilotinib.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Nilotinib.Approved
SpironolactoneThe serum concentration of Nilotinib can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Nilotinib is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Nilotinib can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Nilotinib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Nilotinib can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Nilotinib can be decreased when it is combined with Streptozocin.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Nilotinib.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nilotinib.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Nilotinib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nilotinib.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nilotinib.Approved, Investigational
SumatriptanThe serum concentration of Nilotinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Nilotinib.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nilotinib.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nilotinib.Approved
TacrineThe serum concentration of Nilotinib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Nilotinib.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Nilotinib.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Nilotinib.Approved, Investigational
TAK-390MRThe serum concentration of Nilotinib can be decreased when it is combined with TAK-390MR.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nilotinib resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Nilotinib.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Nilotinib.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Nilotinib.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Nilotinib.Experimental
Taurocholic AcidThe serum concentration of Nilotinib can be increased when it is combined with Taurocholic Acid.Experimental
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Nilotinib.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nilotinib.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Nilotinib.Investigational, Withdrawn
TelaprevirThe serum concentration of Nilotinib can be increased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Nilotinib.Approved
TelithromycinThe serum concentration of Nilotinib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Nilotinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Nilotinib.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Nilotinib.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Nilotinib.Approved
TerazosinThe serum concentration of Nilotinib can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Nilotinib.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Nilotinib.Withdrawn
TeriflunomideThe serum concentration of Nilotinib can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Nilotinib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nilotinib.Approved, Investigational
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Nilotinib.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Nilotinib.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Nilotinib is combined with TG4010.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nilotinib.Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Nilotinib.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nilotinib.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Nilotinib.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Nilotinib.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Nilotinib.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Nilotinib.Approved
TiclopidineThe metabolism of Nilotinib can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Nilotinib.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Nilotinib.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Nilotinib.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Nilotinib.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Nilotinib.Approved
TocilizumabThe serum concentration of Nilotinib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibNilotinib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Nilotinib.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Nilotinib.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nilotinib.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nilotinib.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Nilotinib.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Nilotinib.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nilotinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Nilotinib.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Nilotinib.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Nilotinib.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Nilotinib.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Nilotinib.Approved
TrifluoperazineThe serum concentration of Nilotinib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Nilotinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nilotinib.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Nilotinib.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Nilotinib.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Nilotinib.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Nilotinib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nilotinib.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nilotinib.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nilotinib.Investigational, Withdrawn
VandetanibNilotinib may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Nilotinib.Investigational
VardenafilVardenafil may increase the QTc-prolonging activities of Nilotinib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nilotinib.Approved
VemurafenibNilotinib may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Nilotinib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Nilotinib.Approved
VerapamilThe metabolism of Nilotinib can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nilotinib.Investigational
VilanterolVilanterol may increase the QTc-prolonging activities of Nilotinib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Nilotinib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nilotinib.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Nilotinib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nilotinib.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Nilotinib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Nilotinib.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Nilotinib.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Nilotinib.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Nilotinib.Approved, Investigational
VoriconazoleThe serum concentration of Nilotinib can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nilotinib.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Nilotinib.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Nilotinib.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nilotinib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nilotinib.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Nilotinib.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Nilotinib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Nilotinib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Nilotinib.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Nilotinib.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Nilotinib.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Nilotinib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Nilotinib.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Nilotinib.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Yanling WANG, Jie LI, Vinod Kumar KANSAL, Jirang ZHU, Revital LIFSHITZ-LIRON, Dhirenkumar N. MISTRY, Sanjay L. VASOYA, Sundaraselvan ARIYAMUTHU, Gideon PILARSKI, Xungui HE, “NILOTINIB INTERMEDIATES AND PREPARATION THEREOF.” U.S. Patent US20100016590, issued January 21, 2010.

US20100016590
General References
  1. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. [PubMed:16775235 ]
  2. Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. [PubMed:17929114 ]
  3. Breccia M, Cannella L, Nanni M, Stefanizzi C, Alimena G: Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta Haematol. 2007;118(3):162-4. Epub 2007 Sep 20. [PubMed:17890849 ]
  4. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22. [PubMed:17715389 ]
  5. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H: Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs. 2007 Jul;10(7):468-79. [PubMed:17642017 ]
External Links
ATC CodesL01XE08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (68.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9066
Caco-2 permeable-0.5792
P-glycoprotein substrateNon-substrate0.6879
P-glycoprotein inhibitor IInhibitor0.556
P-glycoprotein inhibitor IIInhibitor0.6002
Renal organic cation transporterNon-inhibitor0.8253
CYP450 2C9 substrateNon-substrate0.8178
CYP450 2D6 substrateNon-substrate0.8547
CYP450 3A4 substrateSubstrate0.5552
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.5739
CYP450 2D6 inhibitorNon-inhibitor0.8275
CYP450 2C19 inhibitorInhibitor0.5554
CYP450 3A4 inhibitorInhibitor0.6784
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7862
Ames testNon AMES toxic0.5204
CarcinogenicityNon-carcinogens0.8175
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6343 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Inhibitor0.8458
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral150 mg/1
CapsuleOral150 mg
CapsuleOral200 mg
CapsuleOral200 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2491632 No2009-11-102023-07-04Canada
US7169791 No2003-07-042023-07-04Us
US8163904 No2008-08-232028-08-23Us
US8293756 No2007-09-252027-09-25Us
US8389537 No2006-07-182026-07-18Us
US8415363 No2006-07-182026-07-18Us
US8501760 No2006-07-182026-07-18Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00201 mg/mLALOGPS
logP4.51ALOGPS
logP4.41ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.86ChemAxon
pKa (Strongest Basic)6.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area97.62 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity152.85 m3·mol-1ChemAxon
Polarizability52.35 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-phenylbenzamides. These are benzamides that are N-linked to a phenyl group via the carboxamide group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzamides
Direct ParentN-phenylbenzamides
Alternative Parents
Substituents
  • N-phenylbenzamide
  • Pyridinylpyrimidine
  • 1-phenylimidazole
  • N-arylamide
  • Aminobenzoic acid or derivatives
  • Benzoic acid or derivatives
  • Aminotoluene
  • Benzoyl
  • Toluene
  • Pyrimidine
  • Pyridine
  • N-substituted imidazole
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Molecular Weight:
122871.435 Da
References
  1. Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. [PubMed:17929114 ]
  2. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22. [PubMed:17715389 ]
  3. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 Jun 19;94(12):1765-9. Epub 2006 May 23. [PubMed:16721371 ]
  4. Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F: Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009 Sep 21;3:89-101. [PubMed:19920925 ]
  5. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M: Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. [PubMed:19822896 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR: Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007 Aug 15;13(16):4874-81. [PubMed:17699867 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Tanaka C, Yin OQ, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H: Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol. 2011 Jan;51(1):75-83. doi: 10.1177/0091270010367428. Epub 2010 Aug 11. [PubMed:20702754 ]
  2. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
  3. Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H: Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther. 2009;31 Pt 2:2459-69. doi: 10.1016/j.clinthera.2009.11.015. [PubMed:20110053 ]
  4. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
  2. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Yin OQ, Gallagher N, Fischer D, Zhao L, Zhou W, Leroy E, Golor G, Schran H: Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig. 2011;31(3):169-79. doi: 10.2165/11538700-000000000-00000. [PubMed:21184622 ]
  2. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
  2. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  3. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  3. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
Comments
comments powered by Disqus
Drug created on October 20, 2007 03:39 / Updated on December 10, 2016 02:39